Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, Schering-Plough Partner to Develop Novel Compound Library

SAN FRANCISCO, Jan. 7 - Exelixis will collaborate with Schering-Plough Research Institute in building a custom-designed compound library, Exelixis CEO George Scangos said on Monday.


The alliance, which Scangos characterized as a "small collaboration not on the level of [the past deals] with Bristol Myers Squibb or Bayer," represents the company's fourth chemistry-oriented relationship in which Exelixis is asked to generate a library of compounds.


Speaking at the 20th annual JPMorgan H&Q Healthcare Conference, held here through Thursday, Scangos said the collaboration allowed both companies to use the compounds in individual drug-discovery programs. Scangos said the alliances brought in revenue while supplying possible lead compounds for Exelixis' own drug-discovery effort.


"The business is dependent on shots on goal," said Scangos, who added that the company would be filing its first Investigational New Drug application for its anticancer compound Rebeccamycin, developed in collaboration with Bristol-Myers Squibb, this year.Two INDs per year starting in 2003 will follow.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.